miR-422a inhibits glioma proliferation and invasion by targeting IGF1 and IGF1R

Oncology Research

Volumn 25, Issue 2, 2017, Pages 187-194

  Wang, Haiyang ^a   Tang, Chongyang ^a   Na, Meng ^a   Ma, Wei ^a   Jiang, Zhenfeng ^a   Gu, Yifei ^a   Ma, Guizhen ^a   Ge, Haitao ^a   Shen, Hong ^a   Lin, Zhiguo ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; Insulin like growth factor 1 (IGF1); Insulin like growth factor 1 receptor (IGF1R); miR 422a

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; MICRORNA; MICRORNA 422A; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; IGF1 PROTEIN, HUMAN; IGF1R PROTEIN, HUMAN; MIRN422 MICRORNA, HUMAN; SOMATOMEDIN RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CORRELATION ANALYSIS; DOWN REGULATION; GENE EXPRESSION; GLIOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN TUMOR; GENE TARGETING; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR INVASION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE TARGETING; GLIOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICRORNAS; NEOPLASM INVASIVENESS; RECEPTORS, SOMATOMEDIN;

EID: 85013645830     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14732772150389     Document Type: Article

References (20)

1. Wen, P. Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359:492-507; 2008.
2. Giese, A.; Bjerkvig, R.; Berens, M. E.; Westphal, M. Cost of migration: Invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21:1624-1636; 2003.
3. Paw, I.; Carpenter, R. C.; Watabe, K.; Debinski, W.; Lo, H. W. Mechanisms regulating glioma invasion. Cancer Lett. 362:1-7; 2015.
4. Bertoli, G.; Cava, C.; Castiglioni, I. MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5:1122-1143; 2015.
5. Chan, B.; Manley, J.; Lee, J.; Singh, S. R. The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 356:301-308; 2015.
6. Winter, J.; Jung, S.; Keller, S.; Gregory, R. I.; Diederichs, S. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11:228-234; 2009.
7. Calin, G. A.; Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6:857-866; 2006.
8. Zheng, G.; Du, L.; Yang, X.; Zhang, X.; Wang, L.; Yang, Y.; Li, J.; Wang, C. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br. J. Cancer 111:1985-1992; 2014.
9. Zhang, J.; Yang, Y.; Yang, T.; Yuan, S.; Wang, R.; Pan, Z.; Yang, Y.; Huang, G.; Gu, F.; Jiang, B.; Lin, C.; Zhou, W. Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis. Hepatology 61:561-573; 2015.
10. Bahador, R.; Taheriazam, A.; Mirghasemi, A.; Torkaman, A.; Shakeri, M.; Yahaghi, E.; Goudarzi, P. K. Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults' age groups and their association with prediction of poor prognosis in human osteosarcoma. Tumour Biol. 37:3091-3095; 2015.
11. Riedemann, J.; Macaulay, V. M. IGF1R signalling and its inhibition. Endocr. Relat. Cancer 13(Suppl. 1):S33-S43; 2006.
12. Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8:915-928; 2008.
13. Wang, Y.; Buggia-Prevot, V.; Zavorka, M. E.; Bleackley, R. C.; MacDonald, R. G.; Thinakaran, G.; Kar, S. Overexpression of the insulin-like growth factor II receptor increases beta-amyloid production and affects cell viability. Mol. Cell. Biol. 35:2368-2384; 2015.
14. Pollak, M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res. 174:49-53; 2007.
15. Davison, Z.; de Blacquiere, G. E.; Westley, B. R.; May, F. E. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: Implications for therapy. Neoplasia 13:504-515; 2011.
16. Rowinsky, E. K.; Youssoufian, H.; Tonra, J. R.; Solomon, P.; Burtrum, D.; Ludwig, D. L. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 13:5549s-5555s; 2007.
17. Sabbatini, P.; Rowand, J. L.; Groy, A.; Korenchuk, S.; Liu, Q.; Atkins, C.; Dumble, M.; Yang, J.; Anderson, K.; Wilson, B. J.; Emmitte, K. A.; Rabindran, S. K.; Kumar, R. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin. Cancer Res. 15:3058-3067; 2009.
18. Wang, Y.; Hailey, J.; Williams, D.; Wang, Y.; Lipari, P.; Malkowski, M.; Wang, X.; Xie, L.; Li, G.; Saha, D.; Ling, W. L.; Cannon-Carlson, S.; Greenberg, R.; Ramos, R. A.; Shields, R.; Presta, L.; Brams, P.; Bishop, W. R.; Pachter, J. A. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. 4:1214-1221; 2005.
19. Cohen, B. D.; Baker, D. A.; Soderstrom, C.; Tkalcevic, G.; Rossi, A. M.; Miller, P. E.; Tengowski, M. W.; Wang, F.; Gualberto, A.; Beebe, J. S.; Moyer, J. D. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11:2063-2073; 2005.
20. Chistiakov, D. A.; Chekhonin, V. P. Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Eur. J. Pharmacol. 684:8-18; 2012.